Cart
sales@molnova.com
LYG-202
CAS No. 1175077-25-4
LYG-202( —— )
Catalog No. M34847 CAS No. 1175077-25-4
LYG-202 is a novel flavonoid with piperazine substitution and antitumor effects in vivo and in vitro.LYG-202 induced apoptosis in MCF-7, MDA-MB-231, and MDA-MB-435 cells, and increased intracellular ROS production.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 56 | Get Quote |
|
| 5MG | 92 | Get Quote |
|
| 10MG | 155 | Get Quote |
|
| 25MG | 342 | Get Quote |
|
| 50MG | 505 | Get Quote |
|
| 100MG | 705 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameLYG-202
-
NoteResearch use only, not for human use.
-
Brief DescriptionLYG-202 is a novel flavonoid with piperazine substitution and antitumor effects in vivo and in vitro.LYG-202 induced apoptosis in MCF-7, MDA-MB-231, and MDA-MB-435 cells, and increased intracellular ROS production.
-
DescriptionLYG-202, a flavonoid, has potent anti-angiogenic and antitumor activity. LYG-202 inhibits VEGF-stimulated HUVEC migration and tube formation. LYG-202 induces cancer cell apoptosis.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetApoptosis
-
RecptorApoptosis | ROS
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1175077-25-4
-
Formula Weight438.52
-
Molecular FormulaC25H30N2O5
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 5 mg/mL (11.40 mM; Ultrasonic (<60°C)
-
SMILESCOc1c(OCCCCN2CCN(C)CC2)cc(O)c2c1oc(cc2=O)-c1ccccc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Chen Y, et al. LYG-202, a newly synthesized flavonoid, exhibits potent anti-angiogenic activity in vitro and in vivo. J Pharmacol Sci. 2010;112(1):37-45.?
molnova catalog
related products
-
Pipobroman
Pipobroman is an anti-cancer drug that probably acts as an alkylating agent.
-
Necrostatin-7
Necrostatin-7 (Necrostatin 7) is an inhibitor of necrotic apoptosis with cardioprotective effects, inhibits RANK-NFATc1 signaling, and attenuates macrophage differentiation into osteoblasts.
-
TD52
TD52 is an orally active inhibitor of cancerous inhibitor of PP2A (CIP2A). TD52 is an Erlotinib derivative and indirectly reduced CIP2A by disturbing Elk1 binding to the CIP2A promoter.
